Morphological damage induced in vivo by Lonidamine on human metastatic cancer cells.
Lonidamine was given to several patients affected with different types of neoplasias growing as metastases both in ascites and pleural effusion, and solid cutaneous metastases. The patients with tumor cells in ascites and pleural effusion were treated with Lonidamine per os or in loco injections. In cutaneous metastases, Lonidamine was administered by different routes: (1) per os; (2) local endoarterial; and (3) in association with hyperthermic perfusion with or without antiblastic drugs.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D006801:Humans; D006979:Hyperthermia, Induced; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008545:Melanoma / Q000473:pathology / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000648:ultrastructure*; D011720:Pyrazoles / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000556:secondary
D000970:Antineoplastic Agents; D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine